个股异动 | 昂利康涨停 左氧氟沙星片注册获批

Core Viewpoint - Angli康's stock surged by 9.99% to 42.81 CNY per share following the announcement of receiving a drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration [1] Company Summary - Angli康's stock opened at a high and quickly reached the daily limit, indicating strong market interest and investor confidence [1] - The company announced on October 19 that it received the drug registration certificate for Levofloxacin Tablets, a third-generation quinolone antibiotic [1] - Levofloxacin is the left-handed optical isomer of Ofloxacin, known for its broad antibacterial spectrum and strong antibacterial action [1] - The approval of Levofloxacin Tablets is expected to enrich the company's product pipeline, potentially leading to increased revenue opportunities [1]